Curriculum Vitae

Personal information

Ivana Tasevska

Work experience

1. Employer: State institute for drug control
   - Start date: 111996
   - End date:
   - Position: pharmaceutical assessor
   - Activities: evaluation of dossier for Quality of pharmaceutical products
   - Country: Czechia
2. Employer: Institute of molecular genetics
   - Start date: 121993
   - End date: 121994
   - Position: scientific assistant
   - Activities: research
   - Country: Czechia
3. Employer: WHO
   - Start date: 052003
   - End date: 022004
   - Position: technical assistent
   - Activities: coordination of group for evalution of dossiers for the pharmaceutical products for TBC, HIV and malaria
   - Country: Switzerland
4. Employer: Ministry of Health
   - Start date: 032004
   - End date: 072004
   - Position: pharmaceutical assessor
   - Activities: evaluation of dossier for Quality of pharmaceutical products
   - Country: Belgium

Education and training

1. Subject: Institute of chemical technology Prague
   - Start date: 091987
   - End date: 061992
   - Qualification: Engineer
   - Organisation:
   - Country: Czechia
2. Subject: Higher Vocational School of Economic Studies
   - Start date: 092017
   - End date: 062020
   - Qualification: Public Administration
   - Organisation: Public Administration
   - Country: Czechia
3. Subject: Higher Vocational School MILLS
   - Start date: 092020
   - End date:
   - Qualification: Pharmaceutical assistant
   - Organisation: practise with work in pharmacy, laboratory skills, Latin, anatomy, pharmacological subjects, pharmacognosis, biochemistry
   - Country: Czechia

Additional information

Publications

1)J_M Cardot , A Garcia_Arieta , P Paixao , I Tasevska , B Davit, Implementing the Biopharmaceutics Classification System in Drug Development: Reconciling Similarities, Differences, and Shared Challenges in the EMA and US_FDA_Recommended Approaches, AAPS J. 2016 Jul;18(4):1039_46. 2) J_M Cardot , A Garcia_Arieta , P Paixao , I Tasevska , B Davit, Implementing the additional strength biowaiver for generics: EMA recommended approaches and challenges for a US_FDA submission, Eur J Pharm Sci . 2018 Jan 1;111:399_408

Projects

Memberships

Other Relevant Information